DelveInsight’s “Necrobiosis Lipoidica Diabeticorum (NLD)- Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Necrobiosis Lipoidica Diabeticorum, epidemiology insights, Necrobiosis Lipoidica Diabeticorum market trends, therapies, and key companies working in the Necrobiosis Lipoidica Diabeticorum Market in the 7MM.
Necrobiosis Lipoidica Diabeticorum Overview
Necrobiosis lipoidica (NL) is a rare, chronic, and idiopathic granulomatous disease of collagen degeneration. It has an associated risk of ulceration and is classically associated with diabetes mellitus, usually type 1. There is a thickening of the blood vessels’ walls and fat deposition. The major complication of the disease is the formation of an ulcer, mainly occurring after trauma. Uncommonly, infections can also occur. Moreover, if necrobiosis lipoidica becomes chronic, it may rarely turn into squamous cell carcinoma.
Necrobiosis Lipoidica Diabeticorum Epidemiology Insights
-
Necrobiosis lipoidica has an increased prevalence in individuals with diabetes, although this association is currently challenging. The incidence among people with diabetes is only 0.3% to 1.2%. Necrobiosis lipoidica precedes diabetes in up to 14% and appears simultaneously in up to 24%, and occurs after diabetes is diagnosed in 62% of cases. There is no proven connection between the level of glycemic control and the likelihood of developing necrobiosis lipoidica.
-
A predominance of 77% in females. Also, the onset in women is younger than in men. Necrobiosis lipoidica has an average age of onset between 30 and 40 years.
Click here to learn more about the Necrobiosis Lipoidica Diabeticorum Market Landscape
The Report Covers the Necrobiosis Lipoidica Diabeticorum Epidemiology Segmented by:
-
Total Necrobiosis Lipoidica Diabeticorum incident cases
-
Total Necrobiosis Lipoidica Diabeticorum prevalent cases
-
Total Necrobiosis Lipoidica Diabeticorum treatment cases
-
Total Necrobiosis Lipoidica Diabeticorum diagnostic cases
Necrobiosis Lipoidica Diabeticorum Market Outlook
The Necrobiosis Lipoidica Diabeticorum market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Necrobiosis Lipoidica Diabeticorum market trends by analyzing the impact of current Necrobiosis Lipoidica Diabeticorum therapies on the market, unmet needs, drivers and barriers, and demand for better technology. This segment gives a thorough detail of the Necrobiosis Lipoidica Diabeticorum market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Necrobiosis Lipoidica Diabeticorum market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, the Necrobiosis Lipoidica Diabeticorum market in 7MM is expected to witness a major change in the study period 2019-2032.
Key Companies Working in the Necrobiosis Lipoidica Diabeticorum Market
-
Novartis Pharmaceuticals
And many others
Necrobiosis Lipoidica Diabeticorum Therapies Covered and Analyzed in the Report
-
Secukinumab
And many others
Learn more about the Key Companies and Emerging Therapies in the Necrobiosis Lipoidica Diabeticorum Market
Table of Contents
-
Key Insights
-
Necrobiosis Lipoidica Diabeticorum Introduction
-
Executive Summary of Necrobiosis Lipoidica Diabeticorum
-
Disease Background and Overview
-
Epidemiology and patient population
-
Necrobiosis Lipoidica Diabeticorum Emerging Therapies
-
Necrobiosis Lipoidica Diabeticorum Market Outlook
-
Market Access and Reimbursement of Therapies
-
Necrobiosis Lipoidica Diabeticorum Market Drivers
-
Necrobiosis Lipoidica Diabeticorum Market Barriers
-
Appendix
-
Report Methodology
-
DelveInsight Capabilities
-
Disclaimer
Learn about the detailed offerings of the report @ Necrobiosis Lipoidica Diabeticorum Market Outlook
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services